MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Continuous use of Keytruda—both before and after surgery ... in its own study when used as an adjuvant therapy after head and neck cancer surgery. Uppaluri admitted that the contribution ...

A priority review designation was granted to Keytruda for some patients with head and neck cancer. A decision submission is due in August. After a trial presented in 2015, the FDA granted a priority ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant ...